DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS

被引：0
|
作者：
Hall, J. [1 ]
Khela, K. [1 ]
Bertwistle, D. [2 ]
Xiao, H. [3 ]
机构：
[1] Adelphi Real World, Bollington, England
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Lawrence Township, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN340
引用
收藏
页码：S482 / S483
页数：2
相关论文
共 50 条
  • [21] Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
    Bai, Y.
    Xu, N.
    Yuan, X.
    Wang, B.
    Li, E.
    Li, X.
    Li, Y.
    Wang, X.
    Yang, S.
    Xu, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [22] Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience
    Soini, Barbara
    Pani, Giuseppe
    Caffo, Orazio
    Frisinghelli, Michela
    Veccia, Antonello
    Brugnara, Sonia
    Caldara, Alessia
    DiPasquale, MariaChiara
    Ferro, Antonella
    Mussari, Salvatore
    Murgia, Viviana
    Russo, Lucianna
    Valduga, Francesco
    Tumulo, Salvatore
    Galligioni, Enzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
    Hirose, Toshiharu
    Yamamoto, Shun
    Kato, Ken
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [24] First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up
    Shen, L.
    Bai, Y.
    Lin, X.
    Li, W.
    Wang, J.
    Zhang, X.
    Pan, H.
    Bai, C.
    Bai, L.
    Cheng, Y.
    Zhang, J.
    Zhong, H.
    Ba, Y.
    Hu, W.
    Xu, R.
    Guo, W.
    Qin, S.
    Yang, N.
    Lu, J.
    Chanaga, C. Amaya
    Soleymani, S.
    Liu, T.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S279 - S279
  • [25] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Bragagnoli, Campos A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Li, M.
    Cullen, D.
    Memaj, A.
    Lei, M.
    Xiao, H.
    Janjigian, Y. Y.
    Ajani, J. A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 79 - 80
  • [26] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.
    Wyrwicz, Lucjan
    Elimova, Elena
    Blum, Steven I.
    Xiao, Hong
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Li, Mingshun
    Kondo, Kaoru
    Moehler, Markus H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC/GEJC/EAC).
    Kakehi, Sumie
    Betts, Keith A.
    Nie, Xiaoyu
    Kitchen, Sophie A.
    Ray, Saurabh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 275 - 275
  • [28] First-line (1L) treatment patterns in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (GC/GEJC/EAC): Data from the Spanish AGAMENON-SEOM registry
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    Gallego Plazas, J.
    Custodio, A.
    Visa, L.
    Martinez de Castro, E.
    Gomez Gonzalez, L.
    Moreno Gutierrez, M.
    Polanco Sanchez, C.
    Xiao, H.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S258 - S258
  • [29] Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada
    Snow, Stephanie
    Gabrielson, Denise
    Lim, Howard
    Tehfe, Mustapha
    Brezden-Masley, Christine
    [J]. CURRENT ONCOLOGY, 2024, 31 (05) : 2552 - 2565
  • [30] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Chen, Clara
    Blum, Steven Michael
    Davenport, Eric
    Wang, Jinyi
    Kondo, Kaoru
    Moehler, Markus H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345